NCT02157298 - Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. | Biotech Hunter

Enrollment

266

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

November 30, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Dapagliflozin 5 mg

Dapagliflozin, a blood glucose lowering drug. Oral dose

DRUG

Placebo tablet

Placebo tablet. Oral dose

Trial Locations (14)

Research Site, Adachi-ku

Research Site, Chitose-shi

Research Site, Chiyoda-ku

Research Site, Chūōku

Research Site, Fukuoka

Research Site, Hirosaki-shi

Research Site, Kamakura-shi

Research Site, Koriyama-shi

Research Site, Mitaka-shi

Research Site, Osaka

Research Site, Ōita

Research Site, Sendai

Research Site, Shizuoka

Research Site, Yokohama